Systemic Therapies for Scarring and Non-Scarring Alopecia

    October 2017
    Carolyn Goh
    From the encyclopedia
    Tofacitinib →

    a JAK inhibitor for alopecia areata and other autoimmune conditions

    Alopecia Areata →

    autoimmune disorder causing patchy hair loss

    Studysummary JAK inhibitors are effective for hair regrowth in severe alopecia areata.
    Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
    The document reviewed systemic therapies for scarring and non-scarring alopecia, highlighting treatments such as sulfasalazine, hydroxychloroquine, simvastatin/ezetimibe, and JAK inhibitors. Sulfasalazine showed promise for alopecia areata, while hydroxychloroquine was ineffective for alopecia totalis. Simvastatin/ezetimibe had potential for hair growth in alopecia areata patients. JAK inhibitors, including tofacitinib and ruxolitinib, were effective in inducing hair regrowth in moderate-to-severe alopecia areata, with studies involving up to 90 patients. Other treatments like abatacept and IL-12/IL-23p40 cytokine antagonism also showed potential in reversing extensive alopecia areata.
    Discuss this study in the Community →

    Research cited in this study

    116 / 116 results